HARBIN, China, Sept. 20, 2012 /PRNewswire/ -- China Botanic
Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the
"Company"), a developer, manufacturer and distributor of botanical
products, bio-pharmaceuticals and Traditional Chinese Medicines
("TCM") in China, today announced
that due to a system error on the Company's part the conference
call scheduled for today, September 20,
2012 was mistakenly cancelled. The management team is
rescheduling the conference call and an announcement will be made
as soon as possible.
About China Botanic Pharmaceutical Inc.
China Botanic Pharmaceutical Inc. is engaged in the research,
development, manufacturing, and distribution of botanical products,
bio-pharmaceutical products, and traditional Chinese medicines
("TCM"), in the People's Republic of
China. All of the Company's products are produced at its
three GMP-certified production facilities in Ah City, Dongfanghong
and Qingyang. The Company distributes its botanical anti-depression
and nerve-regulation products, biopharmaceutical products, and
botanical antibiotic and OTC TCMs through its network of over 3,000
distributors and over 70 sales centers across 24 provinces in
China. For more information,
please visit www.renhuang.com.
Company
Contact:
|
CCG Investor
Relations:
|
China Botanic
Pharmaceutical Inc.
|
Mr. Mark Collinson,
Partner
|
Ms. Portia Tan, IR
Contact
|
Phone: +1-310-954-1343 (Los
Angeles)
|
Tel:
86-451-8260-2162
|
Email:
mark.collinson@ccgir.com
|
Email:
ir@renhuang.com
|
Website:
www.ccgirasia.com
|
SOURCE China Botanic Pharmaceutical Inc.